We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

1 hedge funds and large institutions have $365 invested in ELITE PHARMACEUTICAL in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $180 → $365 (+$185)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KFA
Kelleher Financial Advisors
New York
+$183

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q2 2026 in Review

1 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2026, worth a combined $365 — up 103% from $180 a quarter earlier.

Fund positioning in ELI was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Kelleher Financial Advisors, adding an estimated $183.

  • 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $365 of ELITE PHARMACEUTICAL stock for Q2 2026, up 103% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2026 and 0 closed out.
  • The largest ELITE PHARMACEUTICAL buyer in Q2 2026 was Kelleher Financial Advisors, an estimated $183 added.

Based on aggregated 13F filings for Q2 2026.